Quinazolinone Derivatives Selective ERβ Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for estrogen-dependent pathological conditions often face challenges due to the non-selective binding of estrogen receptors, leading to unwanted side effects on reproductive systems, while targeting estrogen receptor beta (ERβ) could provide beneficial effects for diseases like Alzheimer's, osteoporosis, and cardiovascular diseases without these side effects.
Innovation Solution
Development of novel compounds that selectively modulate ERβ receptors, allowing for the treatment of various conditions such as bone disorders, cardiovascular diseases, and cancer by selectively interacting with ERβ over ERα, thereby minimizing reproductive system side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective estrogen receptor binders are used to treat estrogen-dependent conditions, then therapeutic effect is achieved, but unwanted side effects occur on reproductive systems
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I) that have differentiated binding affinities for ERα and ERβ receptors. The substituents at positions R1-R6 are specifically configured to enhance binding to ERβ while reducing binding to ERα, creating a locally optimized interaction profile that achieves therapeutic effects in ERβ-expressing tissues without affecting ERα-expressing reproductive tissues.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituents at R1-R6 positions, heteroatom types, molecular weight) to optimize the binding characteristics of the compounds. This allows fine-tuning of selectivity ratios between ERβ and ERα binding, achieving the desired balance between therapeutic efficacy and reduction of reproductive system side effects.
2Reliability
If ERβ selective modulators are developed, then beneficial effects are achieved for diseases like Alzheimer's and osteoporosis, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core quinazolinone scaffold (positions 1-4) and substitutable side chains (positions R1-R6). This modular segmentation allows independent optimization of each segment's contribution to ERβ binding affinity and selectivity, making the complex molecule design more systematic and manageable.
Solution Approach 2:
The patent applies universality by creating a general Formula I framework that can generate multiple ERβ-selective compounds through variation of substituents. This single structural framework serves multiple purposes: achieving ERβ selectivity, optimizing binding affinity, and reducing ERα binding, thereby simplifying the overall development process despite the inherent complexity of achieving selective modulation.
Data Source
AI summary
The present application describes compounds according to Formula I, wherein Q, R1, R2 and X are described herein, that are useful as Estrogen Receptor Beta (ERβ) modulators. Additionally, the present application describes pharmaceutical compositions containing the compounds according to Formula I and optionally additional therapeutic agents. Finally, the present application describes methods utilizing the compounds according to Formula I for modulating the function of ERβ in the treatment of diseases and disorders associated with ERβ such as, for example, bone disorders; cardiovascular diseases; hypercholesterolemia; hypertriglyceridemia; vasomotor disorders; urogenital disorders; prostatic hypertrophy; endometrial hyperplasia; cancer and central nervous system disorders, such as, neurodegenerative disorders.